I have addressed many of the points here in prior posts and don't have time to sit alone at my lake house to rehash each point with great detail as an independent auditor would. I'll give you all the points on RapiMed, as it has been an utter disappointment to all. Frankly, I've written this off and have never been excited about this product in the U.S., especially considering the $2 million or so required for the U.S. Launch.
PIMD has also been a disappointment up to this point, but disagree with your overly-dramatic "watered down" theory. I also believe the jury is still out on this business and look forward to what the future holds the the entire drug supply chain and distribution business. They have all the licenses, and my understanding is revenues will begin next month.
As for the convertible notes, I've previously covered my opinion that Bob has stuck to his word and you have covered your opinion.
I disagree with your PIPE financing opinion. The toxic unfriendly convertible notes, GEM deal, and Ironridge deal were far more toxic and have been the true cause of the extreme selling pressure on this stock. There has been no evidence presented that the PIPE investors will dump their shares. I have read your numerous opinions on this issue, but frankly, without this funding, SCRC would be trading well below $0.05 and would likely be heading to the door of insolvency.
To that end, while there is no question that Bob has had many missteps and the company has a storied past, the truly remarkable fact is this company has survived an onslaught of toxicity that very few have survived in the past. And thanks to Bob, not only has survived, it's on the verge of profitability and success that will surpass most people's expectations.
News 
Market Data 
Discover 
AI
